MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, GSK. The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that the available participant population for rare disease studies is often extremely limited and dispersed globally, GSK welcomed an innovative approach to expanding trial

MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park. The new, state-of-the-art facility, will serve as a hub for all Science 37 operations, enabling cross-functional teams with greater opportunities for collaborative problem-solving and integrated solution delivery. Centralizing operations in one facility will enable Science 37 to deliver patient recruitment and study conduct support on behalf of clinical trial sponsors with greater consistency, speed, and quality

MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, disclosed the final figures resulting from its partnership with a biopharmaceutical company focused on infectious disease prevention research. Science 37 contributed to the recruitment and enrollment of an immunocompromised patient cohort for the sponsor's Phase 3 trial. Leveraging its proprietary Virtual Site and Patient Recruitment solutions, Science 37 identified, recruited, medically qualified, and enrolled 129 patients across 36 states within an 8-week timeline, averaging 65 patients per month. As the top-enrolling site, Science 37 successfully randomized and trea

RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets. Leveraging its proprietary Virtual Site and Patient Recruitment solutions, Science 37 efficiently identified, recruited, medically qualified, and enrolled patients without geographic restrictions. "Enrollment delays can be costly and create immense pressure to deliver results," commented Brian Smith, Senior VP of Project Delivery at Science 37. "Traditionally, study teams address this by starting up more sites and/or adding patient

RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., a leader in enhancing patient access to clinical trials, announced the final enrollment figures from its 20-month engagement with a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders. Science 37 augmented the recruitment and enrollment activities taking place at study sites nationwide for this ongoing Phase 2 trial evaluating the effects of EP547 in patients with Cholestatic Pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis. The study protocol mandated a highly specific patient population, requir

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation. The nearly two-week review included, but was not limited to, the Science 37 Metasite™ model and internal processes, technology utilized to support each trial, data integrity, efficacy, subject safety, protocol deviations, collaboration across teams, and, most importantly, Principal Investigator oversight. Conducted between February 26 and March 6, 2024, the first-of-its-kind FDA inspection yielded success with no significant issues identified ("No Action Indicated") and no objectionable

Science 37's Patient Recruitment Recognized in Prestigious International Annual Awards Program for Standout Digital Health & Medical Technology Products and Companies RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., today announced its selection as winner of the "Clinical Efficiency Innovation Award" in the 8th annual MedTech Breakthrough Awards program. MedTech Breakthrough, an independent market intelligence organization, recognized Science 37 for its transformative solution to clinical research patient recruitment. By leveraging its nationwide medical licensure and AI-powered patient screening capabilities, Science 37's Patient Recruitment solu

RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial. Leveraging its proprietary Metasite™ and Patient Recruitment solutions, Science 37 contributed 28% of all randomized study participants over a 15-month enrollment window. Science 37 averaged 44 patients enrolled per month, while each of the 55 brick-and-mortar sites supporting the trial enrolled an average of two participants per month. Science 37 delivered an enrollment velocity 22x greater tha

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., the clinical research industry's leading MetasiteTM, today announced the launch of a stand-alone Patient Recruitment Solution to deliver patients to sites that are eligible, medically reviewed, and fully consented. While traditional central patient recruitment campaigns have proven to be effective in accelerating enrollment, they are fraught with inefficiencies. The majority of referred patients are not fully qualified, do not have a documented medical history, or are not fully informed regarding expectations for the study. Many sites don't have adequate resources to follow up on all their referr

MIAMI, March 12, 2024 /PRNewswire/ -- eMed, LLC ("eMed") today announced the successful completion of the previously announced tender offer by its wholly-owned subsidiary, Marlin Merger Sub Corporation ("Purchaser"), for all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ:SNCE) ("Science 37") at a price of USD 5.75 per share. Continental Stock Transfer & Trust Company, the depositary for the tender offer, has advised Purchaser that, as of 12:00 Midnight, New York City time, at the end of the day of Monday, March 11, 202

4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

3/A - Science 37 Holdings, Inc. (0001819113) (Issuer)

4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

15-12G - Science 37 Holdings, Inc. (0001819113) (Filer)

EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)

EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)

S-8 POS - Science 37 Holdings, Inc. (0001819113) (Filer)

S-8 POS - Science 37 Holdings, Inc. (0001819113) (Filer)

S-8 POS - Science 37 Holdings, Inc. (0001819113) (Filer)

S-8 POS - Science 37 Holdings, Inc. (0001819113) (Filer)

POS AM - Science 37 Holdings, Inc. (0001819113) (Filer)

POS AM - Science 37 Holdings, Inc. (0001819113) (Filer)

8-K - Science 37 Holdings, Inc. (0001819113) (Filer)

Baird analyst Eric Coldwell downgrades Science 37 Hldgs (NASDAQ:SNCE) from Outperform to Neutral and announces $5.75 price target.

U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 75 points on Monday. The Dow traded up 0.03% to 38,121.11 while the NASDAQ rose 0.48% to 15,529.84. The S&P 500 also rose, gaining, 0.19% to 4,900.27. Check This Out: American Airlines To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Monday   Leading and Lagging Sectors   Consumer discretionary shares rose by 0.6% on Monday. In trading on Monday, energy shares fell by 0.8%.   Top Headline   The Federal Reserve Bank of Dallas’s general business activity index for manufacturing in Texas fell 17 points to a reading of -27.4 in January.   Equities Trading UP   Science

Shares of Panbela Therapeutics, Inc. (NASDAQ:PBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 million public offering. Panbela Therapeutics shares dipped 65.5% to $1.47 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Palisade Bio, Inc. (NASDAQ:PALI) shares jumped 133.8% to $1.2250 after the company requested the withdrawal of a recently filed registration statement. Also, the company announced preclinical data of its lead program PALI-2108 at the 2024 Crohn's & Colitis Congress. OneMedNet Corporation (NASDAQ:ONMD) surged 95% to $1.0401. OneMedNet announced participation as an exhibitor at the 15ᵗʰ Annual S

Craig-Hallum analyst Matt Hewitt downgrades Science 37 Hldgs (NASDAQ:SNCE) from Buy to Hold.

Gainers OneMedNet (NASDAQ:ONMD) stock rose 172.1% to $1.39 during Monday's pre-market session. The market value of their outstanding shares is at $44.8 million. Jin Medical International (NASDAQ:ZJYL) shares increased by 68.25% to $299.5. The market value of their outstanding shares is at $2.3 billion. NovaBay Pharmaceuticals (AMEX:NBY) shares increased by 35.54% to $0.22. The company's market cap stands at $1.4 million. Longeveron (NASDAQ:LGVN) stock rose 33.75% to $1.07. The market value of their outstanding shares is at $26.8 million. Palisade Bio (NASDAQ:PALI) shares increased by 24.3% to $0.65. The market value of their outstanding shares is at $5.9 million. Science 37 Hldgs (NASD